NEW YORK – The number of mergers and acquisitions in the molecular diagnostics and omics life science tools space fell 13 percent in 2020, contrasting sharply with the 13 percent increase in the number of deals the industry saw in 2019 and the 12 percent climb it recorded in 2018.
According to an analysis by GenomeWeb, there were 54 deals completed in the MDx/omics tools space in 2020 compared to 62 deals in 2019 and 55 deals in 2018.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
